<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966238</url>
  </required_header>
  <id_info>
    <org_study_id>VAX125-02</org_study_id>
    <nct_id>NCT00966238</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults &gt;= 65 Years of Age</brief_title>
  <official_title>A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults ≥65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VaxInnate Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VaxInnate Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open-label, escalating dose-ranging study to assess the safety,
      reactogenicity, and immunogenicity of four different VAX125 vaccine doses; 0.5 µg, 1.0 µg,
      2.0 µg, or 3.0 µg, delivered i.m. as a single dose vaccination on Day 0. Hypothesis: VAX125
      is safe and immunogenic at one or more of the doses tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 80 community-living adults who are ≥65 years of age will be enrolled across the
      four dose groups. Following vaccination, each subject will remain at the study site for at
      least 30 minutes to be observed for any immediate reactogenicity complaints associated with
      the Day 0 vaccination. Subjects will also be evaluated during clinic visits on Study Days 1,
      7, 14, and 28 following vaccination. In addition, a safety follow-up telephone contact will
      occur on post vaccination Day 3.

      There will be 20 subjects per dose group. Up to 3 study sites will enroll 6-10 subjects per
      dose group over a two-day enrollment period. Progression to the next higher dose group will
      take place only if the Safety Monitoring Committee (SMC) assessment of the 30 (+15) minutes,
      Day 0, and Day 1 post vaccination safety data; Day 3 telephone report: and the Day 0 and Day
      1 serum C-reactive protein (CRP) results concludes that the lower dose was well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Immediate Reactogenicity Complaints</measure>
    <time_frame>within 4 hours following vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Hemagglutinin Inhibition (HAI) Antibody Titers</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>VAX125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HA1 influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAX125</intervention_name>
    <description>STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).</description>
    <arm_group_label>VAX125</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men or women aged 65 or older; female subjects must be post menopausal.

          -  Live in the community, independently or in an assisted living environment

          -  Based on the results of the Short Portable Mental Status Questionnaire (SPMSQ), be
             rated as normal or have no greater than mild severity dementia.

          -  As defined by the Canadian Study of Health and Aging Clinical Frailty Scale
             (CSHA-CFS), fitness ranging from very fit to mildly frail; Classes 1 to 5 of 7.

          -  Healthy volunteers, as determined by medical history, physical examination (PE), vital
             signs, and clinical safety laboratory examinations.

          -  Able to comprehend the study requirements, agree to its provisions, have the ability
             to adhere to the provisions of the study, and give written informed consent prior to
             study entry.

          -  Willing to receive the unlicensed (VAX125) vaccine given as an i.m. injection.

          -  Willing to provide multiple blood specimens collected by venipuncture.

        Exclusion Criteria:

          -  Persons who in the opinion of the Investigator, have a psychiatric illness, a chronic
             illness (e.g., diabetes or liver or kidney disease), or who are taking a concomitant
             therapy or have any other condition that would interfere with the subject's
             participation in the study or interpretation of the study results.

          -  Persons having cancer or have received treatment for cancer within three years
             (persons with a history of cancer who are disease-free without treatment for three
             years or more are eligible.

          -  Persons with impaired immune responsiveness (of any cause), including diabetes
             mellitus.

          -  Persons presently receiving or having a recent history of receiving (within the past
             six months) any medication or therapeutic modality that affects the immune system such
             as allergy shots, immune globulin, interferon, immunomodulators, radiation therapy,
             cytotoxic drugs or drugs known to be frequently associated with significant major
             organ toxicity, or systemic corticosteroids (oral or injectable). Inhaled and topical
             corticosteroids are allowed.

          -  Persons who have had a prior serious reaction to influenza vaccine.

          -  Persons with a history of anaphylactic-type reaction to injected vaccines.

          -  Persons with a history of drug or chemical abuse in the year prior to screening.

          -  Persons currently participating in another research study involving study medications
             (drugs or vaccines) or who have participated within 30 days of vaccination.

          -  Persons who have received blood or blood products within eight weeks prior to
             vaccination or are planning to receive blood or blood products during the study
             period.

          -  Persons who have donated blood or blood products within eight weeks prior to
             vaccination or plan to donate at any time during the study.

          -  Persons with acute disease within 72 hours prior to vaccination defined as the
             presence of a moderate or severe illness as determined by the Investigator through
             medical history and physical examination. Vaccination can be delayed until the subject
             has recovered.

          -  Persons with significant cardiovascular disease e.g., New York Heart Associate (NYHA)
             Class 3 or 4 congestive heart failure; myocardial infarction within the past six
             months; unstable angina, coronary angioplasty within the past six months; uncontrolled
             ventricular cardiac arrhythmias; resting heart rate (HR) &gt;100 beats per minute (bpm)

          -  Persons with a history of chronic obstructive pulmonary disease or history of other
             lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Taylor, MD</last_name>
    <role>Study Director</role>
    <affiliation>VaxInnate Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JCCT</name>
      <address>
        <city>Lanexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <results_first_submitted>June 13, 2011</results_first_submitted>
  <results_first_submitted_qc>June 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2011</results_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited across 3 clinical sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>0.5 µg i.m.</title>
        </group>
        <group group_id="P2">
          <title>1.0 µg i.m.</title>
        </group>
        <group group_id="P3">
          <title>2.0 µg i.m.</title>
        </group>
        <group group_id="P4">
          <title>3.0 µg i.m.</title>
        </group>
        <group group_id="P5">
          <title>5.0 µg i.m.</title>
        </group>
        <group group_id="P6">
          <title>8.0 µg i.m.</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5 µg i.m.</title>
        </group>
        <group group_id="B2">
          <title>1.0 µg i.m.</title>
        </group>
        <group group_id="B3">
          <title>2.0 µg i.m.</title>
        </group>
        <group group_id="B4">
          <title>3.0 µg i.m.</title>
        </group>
        <group group_id="B5">
          <title>5.0 µg i.m.</title>
        </group>
        <group group_id="B6">
          <title>8.0 µg i.m.</title>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.8" spread="6.12"/>
                    <measurement group_id="B2" value="71.2" spread="4.65"/>
                    <measurement group_id="B3" value="71.7" spread="4.16"/>
                    <measurement group_id="B4" value="71.9" spread="4.28"/>
                    <measurement group_id="B5" value="70.7" spread="4.07"/>
                    <measurement group_id="B6" value="70.6" spread="4.91"/>
                    <measurement group_id="B7" value="71.5" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Immediate Reactogenicity Complaints</title>
        <time_frame>within 4 hours following vaccination</time_frame>
        <population>Immediate complaints were vaccination symptoms that were solicited and observed at 30 minutes (+15 minutes) and (±30 minutes) after the vaccination on Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 µg i.m.</title>
          </group>
          <group group_id="O2">
            <title>1.0 µg i.m.</title>
          </group>
          <group group_id="O3">
            <title>2.0 µg i.m.</title>
          </group>
          <group group_id="O4">
            <title>3.0 µg i.m.</title>
          </group>
          <group group_id="O5">
            <title>5.0 µg i.m.</title>
          </group>
          <group group_id="O6">
            <title>8.0 µg i.m.</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Immediate Reactogenicity Complaints</title>
          <population>Immediate complaints were vaccination symptoms that were solicited and observed at 30 minutes (+15 minutes) and (±30 minutes) after the vaccination on Day 0.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Hemagglutinin Inhibition (HAI) Antibody Titers</title>
        <time_frame>28 days after vaccination</time_frame>
        <population>The immunogenicity of the vaccine was evaluated by measuring the number of subjects who demonstrate seroconversion either by developing a measurable titer following vaccination or by showing a significant increase in HAI serum antibody titers post-vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 µg i.m.</title>
          </group>
          <group group_id="O2">
            <title>1.0 µg i.m.</title>
          </group>
          <group group_id="O3">
            <title>2.0 µg i.m.</title>
          </group>
          <group group_id="O4">
            <title>3.0 µg i.m.</title>
          </group>
          <group group_id="O5">
            <title>5.0 µg i.m.</title>
          </group>
          <group group_id="O6">
            <title>8.0 µg i.m.</title>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Hemagglutinin Inhibition (HAI) Antibody Titers</title>
          <population>The immunogenicity of the vaccine was evaluated by measuring the number of subjects who demonstrate seroconversion either by developing a measurable titer following vaccination or by showing a significant increase in HAI serum antibody titers post-vaccination.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.32" lower_limit="14.34" upper_limit="52.04"/>
                    <measurement group_id="O2" value="27.32" lower_limit="15.00" upper_limit="49.77"/>
                    <measurement group_id="O3" value="24.62" lower_limit="11.87" upper_limit="51.09"/>
                    <measurement group_id="O4" value="50.98" lower_limit="29.13" upper_limit="89.22"/>
                    <measurement group_id="O5" value="18.59" lower_limit="10.01" upper_limit="34.53"/>
                    <measurement group_id="O6" value="30.31" lower_limit="15.93" upper_limit="57.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.31" lower_limit="15.79" upper_limit="58.20"/>
                    <measurement group_id="O2" value="38.64" lower_limit="21.21" upper_limit="70.39"/>
                    <measurement group_id="O3" value="50.98" lower_limit="24.72" upper_limit="105.12"/>
                    <measurement group_id="O4" value="105.56" lower_limit="49.64" upper_limit="224.50"/>
                    <measurement group_id="O5" value="66.66" lower_limit="37.85" upper_limit="117.42"/>
                    <measurement group_id="O6" value="154.55" lower_limit="85.63" upper_limit="278.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.87" lower_limit="22.05" upper_limit="83.35"/>
                    <measurement group_id="O2" value="77.27" lower_limit="43.22" upper_limit="138.16"/>
                    <measurement group_id="O3" value="69.64" lower_limit="33.95" upper_limit="142.86"/>
                    <measurement group_id="O4" value="160.00" lower_limit="82.23" upper_limit="311.32"/>
                    <measurement group_id="O5" value="230.44" lower_limit="119.96" upper_limit="442.68"/>
                    <measurement group_id="O6" value="234.25" lower_limit="127.42" upper_limit="430.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.57" lower_limit="23.88" upper_limit="94.76"/>
                    <measurement group_id="O2" value="74.64" lower_limit="44.15" upper_limit="126.21"/>
                    <measurement group_id="O3" value="69.64" lower_limit="33.95" upper_limit="142.86"/>
                    <measurement group_id="O4" value="149.29" lower_limit="78.77" upper_limit="282.93"/>
                    <measurement group_id="O5" value="222.18" lower_limit="113.51" upper_limit="434.89"/>
                    <measurement group_id="O6" value="211.12" lower_limit="120.49" upper_limit="369.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected for 1 year following vaccination. All adverse events were collected for 28 days following vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.5 µg i.m.</title>
        </group>
        <group group_id="E2">
          <title>1.0 µg i.m.</title>
        </group>
        <group group_id="E3">
          <title>2.0 µg i.m.</title>
        </group>
        <group group_id="E4">
          <title>3.0 µg i.m.</title>
        </group>
        <group group_id="E5">
          <title>5.0 µg i.m.</title>
        </group>
        <group group_id="E6">
          <title>8.0 µg i.m.</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David N. Taylor</name_or_title>
      <organization>VaxInnate</organization>
      <phone>609-860-2260</phone>
      <email>david.taylor@vaxinnate.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

